{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:54Z","timestamp":1790630394453,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ucl.2017.12.011","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T13:32:59Z","timestamp":1523280779000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"45","author":[{"given":"Min Yuen","family":"Teo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ucl.2017.12.011_bib1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.ucl.2017.12.011_bib2","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International Collaboration of Trialists","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.011_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.011_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.011_bib5","article-title":"Adjuvant chemotherapy for invasive bladder cancer (individual patient data)","author":"Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.011_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2017.12.011_bib7","article-title":"Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma","author":"Hosogoe","year":"2017","journal-title":"Eur Urol Focus"},{"issue":"12","key":"10.1016\/j.ucl.2017.12.011_bib8","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.011_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A\u00a0systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.ucl.2017.12.011_bib10","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7528","key":"10.1016\/j.ucl.2017.12.011_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.011_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and\u00a0activity of pembrolizumab in patients with locally\u00a0advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10031","key":"10.1016\/j.ucl.2017.12.011_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ucl.2017.12.011_bib14","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.011_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2017.12.011_bib16","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2017.12.011_bib17","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2017.35.15_suppl.4528","article-title":"Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study","volume":"35","author":"Apolo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2017.12.011_bib18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2017.12.011_bib19","series-title":"IMvigor211: a phase III randomized study examining atezolizumab vs. chemotherapy for platinum-treated advanced urothelial carcinoma","author":"Powles","year":"2017"},{"issue":"11","key":"10.1016\/j.ucl.2017.12.011_bib20","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2017.12.011_bib21","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2017.35.15_suppl.4502","article-title":"Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)","volume":"35","author":"O'Donnell","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10064","key":"10.1016\/j.ucl.2017.12.011_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.011_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2017.12.011_bib24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2017.12.011_bib25","first-page":"221","article-title":"Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nature reviews","volume":"14","author":"Funt","year":"2017","journal-title":"Clin Oncol"},{"issue":"18","key":"10.1016\/j.ucl.2017.12.011_bib26","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ucl.2017.12.011_bib27","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ucl.2017.12.011_bib28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ucl.2017.12.011_bib29","series-title":"Efficacy and safety of nivolumab\u00a0+ ipilimumab (N+I) v sunitinib (S) for treatment-na\u00efve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups","author":"Escudier","year":"2017"},{"issue":"2-suppl","key":"10.1016\/j.ucl.2017.12.011_bib30","first-page":"91","article-title":"First results from the phase I\/II CheckMate 032 study","volume":"4","author":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma","year":"2016","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2017.12.011_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.eururo.2014.08.003","article-title":"Conditional survival after radical nephroureterectomy for upper tract carcinoma","volume":"67","author":"Ploussard","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2017.12.011_bib32","first-page":"1662","article-title":"Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis","volume":"189","author":"Roupret","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.011_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urology.2009.10.004","article-title":"A\u00a0population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma","volume":"75","author":"Jeldres","year":"2010","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2017.12.011_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.urology.2010.04.020","article-title":"Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma","volume":"76","author":"Abouassaly","year":"2010","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2017.12.011_bib35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2017.12.011_bib36","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1200\/JCO.2017.35.15_suppl.4510","article-title":"Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B)","volume":"35","author":"Carlo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2017.12.011_bib37","article-title":"Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: results from the National Cancer Data Base","author":"Royce","year":"2017","journal-title":"Urol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2017.12.011_bib38","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2017.35.15_suppl.4562","article-title":"A\u00a0phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors","volume":"35","author":"Apolo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ucl.2017.12.011_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/jco.2014.32.4_suppl.355","article-title":"Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND","volume":"32","author":"Tully","year":"2014","journal-title":"Journal of Clinical Oncology,"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317301532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317301532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:37:28Z","timestamp":1758807448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014317301532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0094014317301532"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2017.12.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733049654.793558871","asserted-by":"object"}]},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2017.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}